Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting
Pre-clinical data demonstrates first-in-class MERTK selective inhibitor with novel mechanism of action Rgenix has initiated IND-enabling studies of RGX-019 FOR IMMEDIATE RELEASE New York, NY – April 3, 2019 – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody
Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting
New York, NY – April 1, 2019- Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that Isabel Kurth, Ph.D., Vice President of Research at Rgenix, will present an abstract about Rgenix’s
Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting
On November 28, 2018, Masoud Tavazoie, Co-Founder and CEO of Rgenix, made a presentation at AACR’s Tumor Immunology and Immunotherapy conference in Miami, Fl. As part of his presentation, Masoud described the LXR/ApoE pathway and its role in regulating the innate
AACR Tumor Immunology and Immunotherapy Conference
AACR Tumor Immunology and Immunotherapy Conference November 27 - 30, 2018 | Loews Miami Beach Hotel, Miami Beach, Florida, USA Wednesday, Nov. 28 - Plenary Session 3: Metabolic Regulation in Tumors: Implications for Therapy Session Chair: Matthew G. Vander Heiden, David H. Koch Institute